These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Gentile I; Coppola N; Buonomo AR; Zappulo E; Borgia G Expert Opin Investig Drugs; 2014 Sep; 23(9):1211-23. PubMed ID: 24848437 [TBL] [Abstract][Full Text] [Related]
4. Current race in the development of DAAs (direct-acting antivirals) against HCV. De Clercq E Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613 [TBL] [Abstract][Full Text] [Related]
5. Progress and development of small molecule HCV antivirals. Ni ZJ; Wagman AS Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954 [TBL] [Abstract][Full Text] [Related]
7. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Halfon P; Sarrazin C Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577 [TBL] [Abstract][Full Text] [Related]
8. Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Klibanov OM; Williams SH; Smith LS; Olin JL; Vickery SB Pharmacotherapy; 2011 Oct; 31(10):951-74. PubMed ID: 21950642 [TBL] [Abstract][Full Text] [Related]
9. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
10. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Gentile I; Zappulo E; Buonomo AR; Borgia G Expert Rev Anti Infect Ther; 2014 Jul; 12(7):775-82. PubMed ID: 24840817 [TBL] [Abstract][Full Text] [Related]
11. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Shah N; Pierce T; Kowdley KV Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127 [TBL] [Abstract][Full Text] [Related]
12. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Flanagan S; Crawford-Jones A; Orkin C Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158 [TBL] [Abstract][Full Text] [Related]
13. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors. Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802 [TBL] [Abstract][Full Text] [Related]
14. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. Wyles DL J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303 [TBL] [Abstract][Full Text] [Related]
15. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Durantel D; Alotte C; Zoulim F Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228 [TBL] [Abstract][Full Text] [Related]
16. Daclatasvir for the treatment of hepatitis C virus infection. Adler H; Lambert JS Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):725-38. PubMed ID: 24882552 [TBL] [Abstract][Full Text] [Related]
17. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. Imran M; Manzoor S; Khattak NM; Khalid M; Ahmed QL; Parvaiz F; Tariq M; Ashraf J; Ashraf W; Azam S; Ashraf M Arch Virol; 2014 May; 159(5):831-46. PubMed ID: 23979177 [TBL] [Abstract][Full Text] [Related]
18. Novel therapies for hepatitis C: insights from the structure of the virus. Fusco DN; Chung RT Annu Rev Med; 2012; 63():373-87. PubMed ID: 21942423 [TBL] [Abstract][Full Text] [Related]